Author

Devanand Joseph

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Bristol-Myers Squibb (United States), Janssen Research & Development (United States)

OpenAlex ID: A5029386449

Nivolumab for Resected Stage III or IV Melanoma at 9 Years

2025 · Paolo A. Ascierto, Michele Del Vecchio, et al. · New England Journal of Medicine · 27

Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy

2013 · Masafumi Fukagawa, Hirotake Kasuga, et al. · Clinical and Experimental Nephrology · 13

Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study

2025 · Sara Lonardi, Iwona Ługowska, et al. · Journal for ImmunoTherapy of Cancer · 4

Abstract CT236: A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the efficacy of guselkumab in subjects with familial adenomatous polyposis

2020 · Eduardo Vilar-Sanchez, Carol Burke, et al. · Cancer Research · 1

616 Pharmacokinetics and safety of a subcutaneous formulation of nivolumab (NIVO SC) monotherapy: updated results from the phase 1/2 CheckMate 8KX study

2023 · Sara Lonardi, Iwona Ługowska, et al. · Journal for ImmunoTherapy of Cancer

Works count: 5

Citation count: 45

H-index: 3

I10-index: 2